Allogene Therapeutics ALLO Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's other income, net (note 6)?
- Allogene Therapeutics (ALLO) reported other income, net (note 6) of $212K in Q1 2026.
- How has Allogene Therapeutics's other income, net (note 6) changed year-over-year?
- Allogene Therapeutics's other income, net (note 6) increased by 130.4% year-over-year, from $92K to $212K.
- What is the long-term trend for Allogene Therapeutics's other income, net (note 6)?
- Over 4 years (2021 to 2025), Allogene Therapeutics's other income, net (note 6) has grown at a -47.1% compound annual growth rate (CAGR), from -$2.74M to $215K.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.